Brief: Rubius Therapeutics Provides Update On Clinical Trial Progress For Lead Oncology Product Candidate
30/06/2020 13:14
June 30 (Reuters) - Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS PROVIDES UPDATE ON CLINICAL TRIAL
PROGRESS
FOR ITS LEAD ONCOLOGY PRODUCT CANDIDATE RTX-240 AND ANNOUNCES
PLANNED LEADERSHIP TRANSITION
* RUBIUS THERAPEUTICS - COMPLETED DOSING OF FIRST
DOSE-ESCALATION
COHORT WITH NO OBSERVED ADVERSE EVENTS TO DATE IN PHASE 1/2
CLINICAL TRIAL OF RTX-240
* RUBIUS THERAPEUTICS - ANDREW OH, CFO WILL DEPART CO
FOLLOWING
COMPLETION OF A TRANSITION PERIOD
* RUBIUS THERAPEUTICS - CO HAS INITIATED A SEARCH FOR ITS
NEXT CFO
Source text for Eikon: ID:nGNX97wfYW
Further company coverage: RUBY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft